| 1. |
National Health and Family Planning Commission of the People’s Republic of China. The Ministry of Health issued a Notice on the plan to set up the banks of umbilical cord blood stem cell. 2001-05-22. [cited 2016-02-12] Available from: http://www.nhfpc.gov.cn/ yzygj/wslgf/201308/d4e 9f5662ed24d0c99c76fc72d21a4ee.shtml
|
|
2.Ministry of Science and Technology of the People’s Republic of China. Notification on national key technology research program and technological basic projects in the 12th Five-Year Plan. 2012-04-20. [cited 2016-02-12] Available from: http://www.most.gov.cn/ tztg/201204/t20 120424_93830.htm
|
|
3.China Food and Drug Administration. Notification on the self-correction of stem cell research and clinical application. 2011-12-16. [cited 2016-02-12] Available from: http://www.sda.gov.cn/WS01/CL0844/68315.html
|
| 4. |
China Food and Drug Administration. A letter on the draft of 《The stem cell clinical trial research management approach (Trial)》and other documents. 2013-03-01. [cited 2016-02-12] Available from: http://www.sda.gov. cn/ WS01/ CL0778/78934.html
|
| 5. |
China Food and Drug Administration. On the issuance of stem cell clinical research management approach (Trial). 2015-07-20. [cited 2016-02-12] Available from: http:// www.sda.gov.cn/WS01/CL0053/127243.html
|
|
6.China Food and Drug Administration. Quality control of stem cell preparations and guidelines for clinical research (trial). 2015-08-21. [cited 2016-02-12] Available from: http://www.sda.gov.cn/WS01/CL1616/ 127242.html
|
|
7.China Food and Drug Administration. Draft of key research and development program on stem cell and translational medicine. 2015-02-26. [cited 2016-02-12] Available from: http://www.most.gov.cn/tztg/201502/t2015 0226_118286.htm
|
|
8.Ji G, Cao Y. Reflections on stem cell science and industrial development of our country. 2015-06-03. [cited 2016-02- 12] Available from: http://finance. people. com.cn/n/2015/ 0603/c1004-27094969.html
|
|
9.Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341:651-4.
|
|
10.Zhao X, Li W, Lv Z, et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009; 461: 86-90.
|
| 11 |
Zhu X, He F, Zeng H, et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet 2014; 46:287-93.
|
|
12.China Industrial Information Network. Analysis for the Medical Industrialization Situation and Trend of China Stem Cell in 2015. 2015-07-27. [cited 2016-02-12] Available from: http://www.chyxx.com/industry/201507/331066.html
|
|
13.Li C, Dong N, Wu H, et al. A novel method for preservation of human corneal limbal tissue. Invest Ophthalmol Vis Sci 2013; 54:4041-7.
|
| 14 |
Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 2011; 20:1679-85.
|
| 15 |
Liu X, Zheng P, Wang X, et al. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther 2014; 5:57.
|
| 16 |
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
|
| 17 |
Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 2012; 10:678-84.
|
|
18.Yuan W, Sipp D, Wang ZZ, et al. Stem cell science on the rise in China. Cell Stem Cell 2012; 10:12-5.
|
